Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumab
Fig 5
T cell immunophenotype proportions after vedolizumab treatment.
Comparisons of median T cell immunophenotype proportions (%) after vedolizumab treatment at week 14 and week 54 between patients with and without clinical remission. Proportions were compared in patients with and without clinical remission using the Mann-Whitney U-test. Treg cells could not be measured in tissue because of low quantities. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. *p < 0.05. Q, quartile.